Incyte (NASDAQ:INCY) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Incyte (NASDAQ:INCY) in a research note released on Monday,Benzinga reports. The brokerage currently has a $135.00 price target on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $90.00 target price on shares of Incyte in a report on Thursday, January 8th. Morgan Stanley set a $102.00 price target on Incyte in a research report on Wednesday, February 11th. Royal Bank Of Canada decreased their price objective on Incyte from $95.00 to $92.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 11th. Barclays raised their target price on shares of Incyte from $116.00 to $117.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Finally, Piper Sandler increased their price objective on shares of Incyte from $102.00 to $110.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Ten research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Incyte has an average rating of “Hold” and an average price target of $104.00.

Incyte Stock Up 1.2%

Incyte stock opened at $97.10 on Monday. The firm has a market capitalization of $19.32 billion, a price-to-earnings ratio of 15.15, a PEG ratio of 0.76 and a beta of 0.84. The company’s 50 day simple moving average is $102.24 and its 200 day simple moving average is $96.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 3.25. Incyte has a fifty-two week low of $53.56 and a fifty-two week high of $112.29.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing the consensus estimate of $1.96 by ($0.16). Incyte had a return on equity of 26.34% and a net margin of 25.03%.The firm had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.35 billion. During the same quarter last year, the business posted $1.43 earnings per share. The company’s revenue for the quarter was up 27.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Incyte will post 4.86 EPS for the current year.

Insider Buying and Selling at Incyte

In related news, insider Thomas Tray sold 2,774 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $100.00, for a total value of $277,400.00. Following the sale, the insider owned 22,973 shares in the company, valued at approximately $2,297,300. This represents a 10.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael James Morrissey sold 4,323 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $97.26, for a total value of $420,454.98. Following the sale, the executive vice president directly owned 27,507 shares of the company’s stock, valued at $2,675,330.82. This represents a 13.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 72,561 shares of company stock worth $7,195,307 over the last 90 days. Company insiders own 17.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. AustralianSuper Pty Ltd acquired a new position in shares of Incyte during the third quarter valued at about $18,085,000. denkapparat Operations GmbH lifted its position in Incyte by 46.1% in the 2nd quarter. denkapparat Operations GmbH now owns 11,292 shares of the biopharmaceutical company’s stock valued at $769,000 after acquiring an additional 3,564 shares in the last quarter. Rakuten Investment Management Inc. acquired a new position in Incyte during the 3rd quarter valued at about $14,646,000. LBP AM SA increased its holdings in Incyte by 33.6% during the 3rd quarter. LBP AM SA now owns 238,705 shares of the biopharmaceutical company’s stock worth $20,245,000 after purchasing an additional 59,974 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Incyte by 38.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 387,605 shares of the biopharmaceutical company’s stock worth $32,873,000 after purchasing an additional 108,645 shares during the last quarter. 96.97% of the stock is owned by institutional investors.

Key Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: EU clears label expansion for Incyte’s oncology drug Zynyz as the first systemic therapy with chemotherapy for advanced squamous cell anal cancer (SCAC) — a new addressable market and commercial opportunity in Europe that also validates the drug’s broader oncology utility. INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and set a $135 price target, signaling analyst conviction of ~39% upside from current levels — a catalyst for momentum investors and buy-side interest. HC Wainwright Reaffirms Buy on INCY
• Positive Sentiment: Coverage highlights Incyte’s strong cash flow generation ahead of a key conference, which supports near-term funding for commercialization and pipeline programs and reduces financing risk. This bolsters the stock’s fundamental outlook. Incyte Momentum Builds With Strong Cash Flows Ahead Of Key Conference
• Neutral Sentiment: Evercore ISI maintained a “hold” stance on Incyte, indicating some analysts remain cautious despite approvals and positive cash flow commentary — a reminder of mixed analyst views. Evercore ISI Remains a Hold on Incyte
• Negative Sentiment: The FDA has rejected Incyte’s application to expand Zynyz’s lung cancer indication, not due to clinical data but because of quality/manufacturing issues at a Catalent facility recently acquired by Novo Nordisk — this regulatory snag delays U.S. label expansion and could push back incremental revenue from that indication. FDA Rejects Incyte’s Lung Cancer Application Over Catalent Plant Issues

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.